Actively Recruiting
Randomized Trial Comparing TAK-928 and Docetaxel in Adults With Advanced or Metastatic Non-Small Cell Lung Cancer After Prior Immunotherapy and Chemotherapy
Led by Takeda · Updated on 2026-11-02
1200
Participants Needed
50
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Non-small cell lung cancer NSCLC is a common type of lung cancer where abnormal cells grow quickly, affecting lung function. This study focuses on advanced stages of squamous and nonsquamous NSCLC that cannot be surgically removed or have spread to other body parts. Researchers are investigating TAK-928, a new drug designed to activate immune cells called T cells to better attack and destroy tumor cells, comparing it to the standard treatment, docetaxel, in adults with this condition. TAK-928 is a bispecific monoclonal antibody administered through intravenous infusion that targets specific immune pathways to stimulate T cells and natural killer cells against cancer. Participants will receive either TAK-928 or docetaxel, also given by IV infusion. Treatment may continue for up to 24 months, with duration depending on individual response and side effects. The trial includes a randomized, parallel design to evaluate the efficacy and safety of TAK-928 compared to docetaxel. Participants will visit the study clinic multiple times for assessments including imaging scans to measure tumor response, laboratory tests, and questionnaires about quality of life and symptoms. Researchers will monitor treatment effects, side effects, and survival outcomes for up to 26 months. Safety and immune response will also be tracked throughout the study, with ongoing evaluations until treatment ends. Participant involvement may last up to two years or more depending on individual circumstances.
CONDITIONS
Brief Title
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Research Team
T
Takeda Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here